LB‐100, a small molecule inhibitor that targets PP2A involved in cell–cell adhesion, can enhance the efficacy of CAIX‐specific CAR‐T‐cell therapy in both in vivo and in vitro models of GBM.163, 164. The gene discussed is CA9; the disease is glioblastoma.